Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)

  • End date
    Sep 21, 2025
  • participants needed
  • sponsor
    Yu jiren
Updated on 21 March 2022


This study is a prospective, single arm, multi-center phase II clinical trial. The primary study objective is to evaluate the safety of tegafur gimeracil oteracil potassium capsule plus oxaliplatin and Camrelizumab as adjuvant therapy in stage III gastric cancer, including the incidences and types of adverse events. The secondary study objective is to observe and evaluate the disease-free survival (DFS), overall survival (OS) and treatment completion rate.


  1. Study population: participants with stage III gastric cancer confirmed by postoperative pathology according to American Joint Committee on Cancer (AJCC) / Union for International Cancer Control (UICC) 8th Tumor Node Metastasis (TNM) staging classification.
  2. Sample size: single arm design was used in this study and 52 participants were estimated to be enrolled.
  3. Research content: In this study, within 4-6 weeks after the completion of the operation, the participants were selected and qualified for this study, and were scheduled to receive 200mg camrelizumab once intravenous infusion on the first day (q3w), then 130mg/m^2 oxaliplatin on the first day (q3w), and tegafur gimeracil oteracil potassium capsule was taken as follow: surface area is less than 1.25, 80mg per day, twice a day; ≥1.25 ~ <1.5, 100mg per day, twice a day; ≥1.5, 120mg per day, twice a day, and oral administration for 1-14 days every 3 weeks. Three weeks as a course of treatment, a total of 8 courses, after treatment, safety visit and survival follow-up will be carried out. A total of 3 years follow-up time is scheduled since the first medication, and the frequency is once every 3-6 months within 2 years, and once every 6-12 months for the third year.
  4. Adverse events (AEs) management: To minimize the risk of AEs, the investigators will monitor carefully to determine whether or not they are within the expected range. The degree of AEs is evaluated according to The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v 4.0). Investigators will also conduct a thorough examination and adopt an appropriate system to take any necessary measures to deal with AEs.

Condition Gastric Cancer Stage III
Treatment Oxaliplatin, Camrelizumab, Tegafur gimeracil oteracil potassium capsule
Clinical Study IdentifierNCT04515615
SponsorYu jiren
Last Modified on21 March 2022


Yes No Not Sure

Inclusion Criteria

Voluntary participation in the clinical study; fully understands and is informed of the study and has signed the Informed Consent Form (ICF)
The gender is not limited. Age: ≥ 18 years and ≤ 75 years old
Gastric or gastroesophageal junction adenocarcinoma confirmed by pathology
Without evidence of distant metastatic disease before operation by imaging
Received D2 or D2+ radical gastrectomy by open surgery (R0 resection)
Stage III gastric cancer confirmed by postoperative pathology (AJCC/UICC 8th TNM staging classification)
Participants with a performance status of 0 ~ 1 on the Eastern Cooperative Oncology Group (ECOG) within 7 days before the first dose of study treatment
Life expectancy ≥ 6 months
The functions of the vital organs meet requirements as follow (within 14 days before the first dose of study treatment, participant has not received treatment of blood transfusion, albumin, recombinant human thrombopoietin or granulocyte stimulating factor)
Hematological function:
White blood cell count (WBC): 3.5 × 10 ^ 9 / L ~12.0 × 10 ^ 9 / L;
Absolute neutrophil count (ANC) ≥ 1.5 × 10 ^ 9 / L;
Platelet count (PLT) ≥ 100 × 10 ^ 9 / L;
Hemoglobin (Hb) ≥ 90 g / L
Hepatic function:
Total bilirubin (TBIL) ≤ 1.5 × ULN (upper limit of normal)
Aspartate aminotransferase (AST) ≤ 2.5 × ULN
Alanine aminotransferase (ALT) ≤ 2.5 × ULN
Albumin (ALB) ≥ 30 g / L
Renal function:
Creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance ≥ 60 ml / min for those with creatinine level > 1.5 × ULN
Coagulation function:
International normalized ratio (INR) ≤ 1.5
Prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN
Female of childbearing age must meet requirements: urine pregnancy test must be
negative within 7 days before the first dose of study treatment, and she must
agree to use adequate contraception methods or keep abstinence (starting with
the ICF is signed through 120 days after the last dose of camrelizumab, or 180
days after the last dose of chemotherapy, whichever is longer, and should not
be breastfeeding. For the male participants must meet requirements: agree to
use adequate contraception methods or keep abstinence (starting with the ICF
is signed through 120 days after the last dose of camrelizumab, or 180 days
after the last dose of chemotherapy, whichever is longer)

Exclusion Criteria

Received previous chemotherapy, radiotherapy, targeted therapy or immunotherapy
Previous or concurrent have other active malignant tumors (except for basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, prostate cancer or cervical cancer or breast cancer in situ that has undergone curative therapy)
Existence of unrecovered complications after radical gastrectomy before the first dose of study treatment (including but not limited to: infection, gastrointestinal bleeding/ obstruction, anastomotic fistula, pancreatic fistula and anastomotic stenosis)
Myocardial infarction within 6 months before the first dose of study treatment, uncontrolled angina, arrhythmia which need medical intervention (including but not limited to cardiac pacemaker), congestive heart failure (New York Heart Association (NYHA) class III or IV), echocardiogram shows left ventricular ejection fraction (LVEF) < 50%
Participants with active infection within 14 days before the first dose of study treatment which need medical intervention
Participants with active tuberculosis
Previous or concurrent diagnosed with interstitial lung disease by imaging or symptoms
Any of the following test is positive: Human Immunodeficiency Virus (HIV) antibody, Hepatitis B surface Antigen (HBsAg), or Hepatitis C Virus (HCV) antibody
Females who are pregnant or breastfeeding or expecting to conceive during the study period
Participants who need long-term systemic steroid therapy (> 10 mg/d prednisone equivalent) or any other form of immunosuppressive therapy within 14 days before the first dose of study treatment or during the study period
Concurrent or previous have severe allergic reaction to any antibody-based drugs
Existence of any concurrent autoimmune disease, excepting participants with diabetes mellitus type I, hypothyroidism requiring only hormone replacement therapy and skin diseases without systemic treatment (such as vitiligo, psoriasis or alopecia)
Existence of chronic diarrhea (watery diarrhea: ≥ 5 times per day)
Receive live vaccines within 28 days before the first dose of study treatment or during the study period, excepting inactivated viral vaccines for seasonal influenza
Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation
Existence of systemic disease that is difficult to control despite treatment with several agents, for example, diabetes mellitus, hypertension, etc
Existence of other serious physical or mental diseases or serious laboratory abnormalities that may increase the risk of participating in the study. Participants who were judged unsuitable as subjects of this trial by investigator
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note